Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft Tissue

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject or authorized representative has provided informed consent.~* Subject is ≥ 18 years old.~* Subject is scheduled for nonemergent surgery where a topical hemostatic agent would be used to control bleeding emanating from a tissue bed following organ dissection or removal or a bleeding tumor tissue bed following resection or dissection, via an open approach.~* Subject is willing and able to comply with all aspects of the treatment and evaluation schedule.~* Subject has an appropriate Target Bleeding Site (TBS) during the surgical procedure.~* TBS bleeding assessment is Type 2 or 3 (refer to table in protocol).~Exclusion Criteria:~* Subject is pregnant (documented by a positive pregnancy test) or is actively breast-feeding.~* Subject has an estimated life expectancy of less than 6 months.~* Subject is scheduled for another planned surgery and the subsequent surgery would jeopardize the previous application of study treatment.~* Subject is undergoing emergency surgery, i.e. lifesaving procedures performed where patient is in imminent danger of death.~* Subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with the study.~* Subject has an active local infection at the TBS.~* The investigator determines that participation in the study may jeopardize teh safety or welfare of the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Veriset™ Hemostatic Patch (Type: EXPERIMENTAL): Topical hemostat

Based on this trial design, predict the completion outcome and termination type (if applicable).